Ageing and apoE change DHA homeostasis: Relevance to age-related cognitive decline

Proceedings of the Nutrition Society

Volumn 73, Issue 1, 2014, Pages 80-86

  Hennebelle, Marie ^a   Plourde, Mélanie ^a   Chouinard Watkins, Raphaël ^a   Castellano, Christian Alexandre ^a   Barberger Gateau, Pascale ^b   Cunnane, Stephen C ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b INSERM   (France)

Author keywords

Ageing: ApoE; Alzheimer's disease; Cognition; Docosahexaenoic acid

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; CARBON 13; DOCOSAHEXAENOIC ACID; FISH OIL; FISH PROTEIN; OMEGA 3 FATTY ACID; TRACER;

AGING; ALZHEIMER DISEASE; AUSTRALIAN; AUTOPSY; CONFERENCE PAPER; FAT INTAKE; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FISH; GENETIC POLYMORPHISM; HUMAN; LIPID HOMEOSTASIS; MENTAL DETERIORATION; NONHUMAN; PHYSIOLOGICAL PROCESS; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; PROTEIN POLYMORPHISM;

AGING; ALZHEIMER DISEASE; APOLIPOPROTEINS E; COGNITION DISORDERS; DIET; DIETARY FATS; DOCOSAHEXAENOIC ACIDS; FOOD HABITS; HOMEOSTASIS; HUMANS; NUTRITIONAL STATUS;

EID: 84893926752     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665113003625     Document Type: Article

References (83)

1. Blennow K, de Leon MJ & Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
2. Corder EH, Saunders AM, Strittmatter WJ et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
3. Gomez-Pinilla F (2008) Brain foods: the effects of nutrients on brain function. Nat Rev Neurosci 9, 568-578.
4. Alles B, Samieri C, Feart C et al. (2012) Dietary patterns: a novel approach to examine the link between nutrition and cognitive function in older individuals. Nutr Res Rev 25, 207-222.
5. Crawford MA, Bloom M, Broadhurst CL et al. (1999) Evidence for the unique function of docosahexaenoic acid during the evolution of the modern hominid brain. Lipids 34, Suppl, S39-S47.
6. Cunnane SC, Ryan MA, Nadeau CR et al. (2003) Why is carbon from some polyunsaturates extensively recycled into lipid synthesis' Lipids 38, 477-484.
7. Gavino GR & Gavino VC (1991) Rat liver outer mitochondrial carnitine palmitoyltransferase activity towards long-chain polyunsaturated fatty acids and their CoA esters. Lipids 26, 266-270.
8. Leyton J, Drury PJ & Crawford MA (1987) Differential oxidation of saturated and unsaturated fatty acids in vivo in the rat. Br J Nutr 57, 383-393.
9. Plourde M & Cunnane SC (2007) Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab 32, 619-634.
10. Skeaff CM & Miller J (2009) Dietary fat and coronary heart disease: summary of evidence from prospective cohort and randomised controlled trials. Ann Nutr Metab 55, 173-201.
11. Innis SM (2007) Dietary (n-3) fatty acids and brain development. J Nutr 137, 855-859.
12. Cunnane SC, Plourde M, Pifferi F et al. (2009) Fish, docosahexaenoic acid and Alzheimer's disease. Prog Lipid Res 48, 239-256.
13. Yaffe K (2010) Treatment of Alzheimer disease and prognosis of dementia: time to translate research to results. JAMA 304, 1952-1953.
14. Mazereeuw G, Lanctot KL, Chau SA et al. (2012) Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol Aging 33, 1482, e1417-e1429.
15. Sydenham E, Dangour AD & Lim WS (2012) Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev 6, CD005379.
16. Stonehouse W, Conlon CA, Podd J et al. (2013) DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. Am J Clin Nutr 97, 1134-1143.
17. Yurko-Mauro K, McCarthy D, Rom D et al. (2010) Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 6, 456-464.
18. Sinn N, Milte CM, Street SJ et al. (2012) Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr 107, 1682-1693.
19. Quinn JF, Raman R, Thomas RG et al. (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 304, 1903-1911.
20. Fotuhi M, Mohassel P & Yaffe K (2009) Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol 5, 140-152.
21. Barberger-Gateau P, Feart C, Letenneur et al. (2013) Dietary patterns and dementia. In Chronic Medical Disease and Cognitive Aging: Toward a Healthy Body and Brain pp. 197-224 [Yaffe K, editor]. United States: Oxford University Press.
22. Kim HY, Akbar M & Kim YS (2010) Phosphatidylserine-dependent neuroprotective signaling promoted by docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids 82, 165-172.
23. Bazan NG, Molina MF & Gordon WC (2011) Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu Rev Nutr 31, 321-351.
24. Sidhu VK, Huang BX & Kim HY (2011) Effects of docosahexaenoic acid on mouse brain synaptic plasma membrane proteome analyzed by mass spectrometry and (16)O/(18)O labeling. J Proteome Res 10, 5472-5480.
25. Calon F & Cole G (2007) Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot Essent Fatty Acids 77, 287-293.
26. Boudrault C, Bazinet RP & Ma DW (2009) Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer's disease. J Nutr Biochem 20, 1-10.
27. Barberger-Gateau P, Samieri C, Feart C et al. (2011) Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype. Curr Alzheimer Res 8, 479-491.
28. Brenna JT & Diau GY (2007) The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition. Prostaglandins Leukot Essent Fatty Acids 77, 247-250.
29. Oster T & Pillot T (2010) Docosahexaenoic acid and synaptic protection in Alzheimer's disease mice. Biochimica et Biophysica Acta - Mol Cell Biol Lipids 1801, 791-798.
30. Connor WE, Neuringer M & Reisbick S (1991) Essentiality of omega 3 fatty acids: evidence from the primate model and implications for human nutrition. World Rev Nutr Diet 66, 118-132.
31. Novak EM, Dyer RA & Innis SM (2008) High dietary omega-6 fatty acids contribute to reduced docosahexaenoic acid in the developing brain and inhibit secondary neurite growth. Brain Res 1237, 136-145.
32. Soderberg M, Edlund C, Kristensson K et al. (1991) Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 26, 421-425.
33. Lukiw WJ, Cui JG, Marcheselli VL et al. (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 115, 2774-2783.
34. Arsenault LN, Matthan N, Scott TM et al. (2009) Validity of estimated dietary eicosapentaenoic acid and docosahexaenoic acid intakes determined by intervieweradministered food frequency questionnaire among older adults with mild-to-moderate cognitive impairment or dementia. Am J Epidemiol 170, 95-103.
35. Astarita G, Jung KM, Berchtold NC et al. (2010) Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS ONE 5, e12538.
36. Boston PF, Bennett A, Horrobin DF et al. (2004) Ethyl- EPA in Alzheimer's disease-a pilot study. Prostaglandins Leukot Essent Fatty Acids 71, 341-346.
37. Brooksbank BW & Martinez M (1989) Lipid abnormalities in the brain in adult Down's syndrome and Alzheimer's disease. Mol Chem Neuropathol 11, 157-185.
38. Cherubini A, Andres-Lacueva C, Martin A et al. (2007) Low plasma N-3 fatty acids and dementia in older persons: The InCHIANTI study. J Gerontol A, Biol Sci Med Sci 62, 1120-1126.
39. Conquer JA, Tierney MC, Zecevic J et al. (2000) Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 35, 1305-1312.
40. Corrigan FM, Van Rhijn AG, Ijomah G et al. (1991) Tin and fatty acids in dementia. Prostaglandins Leukot Essent Fatty Acids 43, 229-238.
41. Corrigan FM, Horrobin DF, Skinner ER et al. (1998) Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. Int J Biochem Cell Biol 30, 197-207.
42. Cunnane S, Schneider J, Tangney C et al. (2012) Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. J Alzheimer's Dis 29, 691-697.
43. Fraser T, Tayler H & Love S (2010) Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease. Neurochem Res 35, 503-513.
44. Guan Z, Wang Y, Cairns NJ et al. (1999) Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol 58, 740-747.
45. Laurin D, Verreault R, Lindsay J et al. (2003) Omega-3 fatty acids and risk of cognitive impairment and dementia. J Alzheimer's Dis 5, 315-322.
46. Prasad MR, Lovell MA, Yatin M et al. (1998) Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 23, 81-88.
47. Selley ML (2007) A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease. Neurobiol Aging 28, 1834-1839.
48. Skinner ER, Watt C, Besson JA et al. (1993) Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain 116(Pt 3), 717-725.
49. Tully AM, Roche HM, Doyle R et al. (2003) Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 89, 483-489.
50. Svennerholm L, Boström K & Jungbjer B (1997) Changes in weight and compositions of major membrane components of human brain during the span of adult human life of Swedes. Acta Neuropathol 94, 345-352.
51. Aizenstein HJ, Nebes RD, Saxton JA et al. (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65, 1509-1517.
52. Braak H & Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18, 351-357.
53. Duyckaerts C & Hauw JJ (1997) Prevalence, incidence and duration of Braak's stages in the general population: can we know' Neurobiol Aging 18, 362-369; discussion 389-392.
54. Umhau JC, Zhou W, Carson RE et al. (2009) Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. J Lipid Res 50, 1259-1268.
55. Chen CT, Green JT, Orr SK et al. (2008) Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins Leukot Essent Fatty Acids 79, 85-91.
56. Serhan CN & Petasis NA (2011) Resolvins and protectins in inflammation resolution. Chem Rev 111, 5922-5943.
57. Cunnane SC, Chouinard-Watkins R, Castellano CA et al. (2013) Docosahexaenoic acid homeostasis, brain aging and Alzheimer's disease: can we reconcile the evidence' Prostaglandins Leukot Essent Fatty Acids 88, 61-70.
58. Wang DC, Sun CH, Liu LY et al. (2012) Serum fatty acid profiles using GC-MS and multivariate statistical analysis: potential biomarkers of Alzheimer's disease. Neurobiol Aging 33, 1057-1066.
59. Ronnemaa E, Zethelius B, Vessby B et al. (2012) Serum fatty-acid composition and the risk of Alzheimer's disease: a longitudinal population-based study. Eur J Clin Nutr 66, 885-890.
60. Heude B, Ducimetiere P & Berr C (2003) Cognitive decline and fatty acid composition of erythrocyte membranes-the EVA Study. Am J Clin Nutr 77, 803-808.
61. Schaefer EJ, Bongard V, Beiser AS et al. (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 63, 1545-1550.
62. Kroger E, Verreault R, Carmichael PH et al. (2009) Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. Am J Clin Nutr 90, 184-192.
63. Dullemeijer C, Durga J, Brouwer IA et al. (2007) n 3 fatty acid proportions in plasma and cognitive performance in older adults. Am J Clin Nutr 86, 1479-1485.
64. Beydoun MA, Kaufman JS, Satia JA et al. (2007) Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 85, 1103-1111.
65. Whalley LJ, Deary IJ, Starr JM et al. (2008) n-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: an observational follow-up study in late adulthood. Am J Clin Nutr 87, 449-454.
66. Samieri C, Feart C, Proust-Lima C et al. (2011) omega-3 fatty acids and cognitive decline: modulation by ApoEepsilon4 allele and depression. Neurobiol Aging 32, 2317, e2313-e2322.
67. Plourde M, Chouinard-Watkins R, Vandal M et al. (2011) Plasma incorporation, apparent retroconversion and beta-oxidation of 13C-docosahexaenoic acid in the elderly. Nutr Metab (Lond) 8, 5.
68. Vandal M, Freemantle E, Tremblay-Mercier J et al. (2008) Plasma omega-3 fatty acid response to a fish oil supplement in the healthy elderly. Lipids 43, 1085-1089.
69. Millar JS, Lichtenstein AH, Cuchel M et al. (1995) Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men. J Lipid Res 36, 1155-1167.
70. Jack CR Jr, Knopman DS, Jagust WJ et al. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
71. Jack CR Jr, Petersen RC, Xu YC et al. (1998) Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol 43, 303-310.
72. Chouinard-Watkins R, Rioux-Perreault C, Fortier M et al. (2013) Disturbance in uniformly 13C-labelled docosahexaenoic acid metabolism in elderly humans carrying apolipoprotein E epsilon 4 allele. Br J Nutr 30, 1-9.
73. Plourde M, Vohl MC, Vandal M et al. (2009) Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoE epsilon4 but not by the common PPARalpha L162V polymorphism in men. Br J Nutr 102, 1121-1124.
74. Huang TL, Zandi PP, Tucker KL et al. (2005) Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 65, 1409-1414.
75. Barberger-Gateau P, Raffaitin C, Letenneur L et al. (2007) Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 69, 1921-1930.
76. Harris WS, Mozaffarian D, Lefevre M et al. (2009) Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J Nutr 139, 804S-819S.
77. Kris-Etherton PM, Grieger JA & Etherton TD (2009) Dietary reference intakes for DHA and EPA. Prostaglandins Leukot Essent Fatty Acids 81, 99-104.
78. Meyer BJ (2011) Are we consuming enough long chain omega-3 polyunsaturated fatty acids for optimal health' Prostaglandins Leukot Essent Fatty Acids 85, 275-280.
79. Sanders TA, Hinds A & Pereira CC (1989) Influence of n-3 fatty acids on blood lipids in normal subjects. J Intern Med Suppl 731, 99-104.
80. James MJ, Ursin VM & Cleland LG (2003) Metabolism of stearidonic acid in human subjects: comparison with the metabolism of other n-3 fatty acids. Am J Clin Nutr 77, 1140-1145.
81. Fokkema MR, Brouwer DA, Hasperhoven MB et al. (2000) Short-term supplementation of low-dose gammalinolenic acid (GLA), alpha-linolenic acid (ALA), or GLA plus ALA does not augment LCP omega 3 status of Dutch vegans to an appreciable extent. Prostaglandins Leukot Essent Fatty Acids 63, 287-292.
82. Horrobin D, Fokkema MR & Muskiet FA (2003) The effects on plasma, red cell and platelet fatty acids of taking 12 g/day of ethyl-eicosapentaenoate for 16 months: dihomogammalinolenic, arachidonic and docosahexaenoic acids and relevance to Inuit metabolism. Prostaglandins Leukot Essent Fatty Acids 68, 301-304.
83. Lopez LB, Kritz-Silverstein D & Barrett Connor E (2011) High dietary and plasma levels of the omega-3 fatty acid docosahexaenoic acid are associated with decreased dementia risk: the Rancho Bernardo study. J Nutr Health Aging 15, 25-31.